ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder
The position of the American College of Medical Toxicology (ACMT), endorsed by the American Academy of Clinical Toxicology, the American Academy of Emergency Medicine, and the American College of Emergency Physicians is as follows: To increase access for patients to receive treatment for opioid use disorder in the United States, we strongly recommend removing the waiver (“X-waiver”) requirement for buprenorphine prescribing.
Current US law requires prescribers to obtain a waiver (“X-waiver”) for outpatient prescription of buprenorphine . The ongoing epidemic of opioid overdose deaths in North America represents a major public health crisis, with more than 48,000 Americans estimated to have died from opioid overdose in 2017 alone . Opioid use disorder (OUD) is a chronic medical condition that can be treated with pharmacological therapies. In response to growing evidence, there is consensus within the healthcare community that opioid agonist therapy (OAT) is the best...
KeywordsBuprenorphine Waiver X-waiver Opioid use disorder Opioid agonist therapy
Sources of Funding
Compliance with Ethical Standards
Conflict of Interest
While individual practices may differ, this is the position of the American College of Medical Toxicology at the time written, after a review of the issue and pertinent literature.
- 1.Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2018; Epub ahead of print.Google Scholar
- 2.Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2018. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm Accessed: May 21, 2019.
- 3.Mancher M, Leshner AI. Medications for Opioid Use Disorder Save Lives. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder: Washington (DC): National Academies Press (US); 2019 Mar. http://www.nationalacademies.org/hmd/Reports/2019/medications-for-opioid-use-disorder-savelives.aspx. Accessed July 1, 2019.
- 10.Drug Enforcement Administration Office of Diversion Control Drug & Chemical Evaluation Section: Buprenorphine. https://www.deadiversion.usdoj.gov/drug_chem_info/buprenorphine.pdf. Accessed 1 Feb 2019
- 11.Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of comparative clinical effectiveness, cost-effectiveness and guidelines [internet]. Ottawa (ON): Canadian agency for Drugs and Technologies in Health; 2016 Sep 2.Google Scholar
- 13.Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2018.Google Scholar
- 18.Marteau D, Mcdonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open. 2015;5:e007629.Google Scholar
- 23.Lowenstein M, Kilaru A, Perrone J, Meisel Z, Delgado MK. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. [published online ahead of print February 18 2019]. Am J Emerg Med. 2019. https://doi.org/10.1016/j.ajem.2019.02.025.